ZimVie has entered a deal to be acquired by an affiliate of ARCHIMED, an investment firm focused on healthcare industries.

Stockholders will receive $19 in cash for each share of ZimVie common stock outstanding at the transaction’s close, corresponding to an enterprise value of about $730 million.

“This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years,” said Vafa Jamali, chairman and CEO of ZimVie. “Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.”

The deal is expected to close by the end of 2025, subjecting to satisfaction of customary closing conditions. Before the deal’s closing, ZimVie will operate business as usual, separately from ARCHIMED.

After the deal closes, the company will become privately held and no longer be listed on the Nasdaq stock exchange.

ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures.

“We’re excited to partner with ZimVie and its talented team,” said André-Michel Ballester, Managing Partner at ARCHIMED. “The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.”